CD5 and neoplasm: The immunohistochemical examination identified tumor proliferation with small B-cells, positive for CD20 (positive marker in B-cells), negative for Cyclin D1, negative for CD5 (positive marker in T-cells), with a kappa/lambda ratio of 5/1 (monoclonal dominance of kappa light chains) (Fig. 3A, B).